Your session is about to expire
← Back to Search
Enzyme Replacement Therapy
A Study of JR-171 in Patients With Mucopolysaccharidosis I
Phase 1 & 2
Waitlist Available
Research Sponsored by JCR Pharmaceuticals Co., Ltd.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Timeline
Screening 3 weeks
Treatment Varies
Follow Up part1: 1,2,3,4 week, part2: 1, 4, 12 week
Awards & highlights
No Placebo-Only Group
Summary
This trial is testing a new treatment for patients with mucopolysaccharidosis type I (MPS I). The goal is to see if the treatment is safe and how it behaves in the body. The treatment likely works by replacing or supplementing a missing enzyme. Laronidase, an enzyme replacement therapy, has been used to treat MPS I by supplementing the deficient alpha-L-iduronidase enzyme.
Eligible Conditions
- Hurler Syndrome
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ part1: 1,2,3,4 week, part2: 1, 4, 12 week
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~part1: 1,2,3,4 week, part2: 1, 4, 12 week
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Number of participants with Adverse Events
Secondary study objectives
Assessment of pharmacokinetic parameter
Change From Baseline in Echocardiography.
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
2Treatment groups
Experimental Treatment
Group I: Part2 JR-171Experimental Treatment1 Intervention
Drug: JR-171 IV infusion, dose escalation, low dose, high dose
Group II: Part1 JR-171Experimental Treatment1 Intervention
Drug: JR-171 IV infusion, dose escalation
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
JR-171 (lepunafusp alfa)
2020
Completed Phase 2
~20
Find a Location
Who is running the clinical trial?
JCR Pharmaceuticals Co., Ltd.Lead Sponsor
12 Previous Clinical Trials
302 Total Patients Enrolled